Skip to main content
. 2019 Jul 19;5(2):151–163. doi: 10.1007/s41030-019-0096-8

Table 1.

Patient disposition through week 24

Status, n (%) Vismodegib 150 mg/day + pirfenidone ≤ 2403 mg/day (N = 21)
Completed 24-week treatment phase 15 (71.4)
Completed safety follow-up 15 (71.4)
Discontinued 24-week treatment phase 6 (28.6)
 Adverse event 4 (19.0)
 Withdrawal by patient 1 (4.8)
 Other 1 (4.8)